Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Design Therapeutics, Inc. Common Stock

DSGN

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Last trade $9.80
Day change -$0.125 (-1.26%)
Day range $9.53 – $10.25
Volume 140,413
Market cap $635M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$635.24M
Price / earnings
—
Price / book
3.14×
Price / sales
—
EV / sales
—
EV / EBITDA
-7.59×

Profitability

Earnings per share
-$1.16
Return on assets
-34.17%
Return on equity
-36.64%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
16.78×
Quick ratio
16.78×
Cash ratio
1.2×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$59.37M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for DSGN, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$5.3M$5.79M$5.33M$4.74M$4.72M$5.83M$5.04M$4.54M
Research and development$16.93M$16.39M$14.38M$13.43M$14.59M$15.74M$15.38M$12.16M
Total operating expenses$22.23M$22.18M$19.71M$18.17M$19.31M$21.57M$20.42M$16.69M
Operating income-$22.23M-$22.18M-$19.71M-$18.17M-$19.31M-$21.57M-$20.42M-$16.69M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$20.29M-$20.17M-$17.64M-$16M-$17M-$19.08M-$17.72M-$13.65M
Income taxes$0$0$0$0$0$0$0$0
Net income-$20.29M-$20.17M-$17.64M-$16M-$17M-$19.08M-$17.72M-$13.65M
Net income attributable to common shareholders-$20.29M-$20.17M-$17.64M-$16M-$17M-$19.08M-$17.72M-$13.65M
EBITDA-$22.09M-$22.03M-$19.55M-$18.01M-$19.16M-$21.42M-$20.26M-$16.55M
Basic earnings per share-$0.32-$0.32-$0.29-$0.27-$0.30-$0.34-$0.31-$0.24
Diluted earnings per share-$0.32-$0.32-$0.29-$0.27-$0.30-$0.34-$0.31-$0.24

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia

Design Therapeutics announced positive Phase 1/2 data from its RESTORE-FA trial showing DT-216P2 demonstrated dose-dependent clinical improvements in Friedreich ataxia patients after four weeks of treatment, including improvements in mFARS scores, upright stability, and fatigue. The drug showed comprehensive biomarker activity with 65% increase in FXN mRNA and 22-27% increase in FXN protein levels. The company plans to advance toward registrational development with updates expected in Q4 2026.

GlobeNewswire Inc.

Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026

Design Therapeutics announced it will present Phase 1/2 RESTORE-FA trial data for DT-216P2, its experimental treatment for Friedreich's ataxia, on May 18, 2026. The company is advancing multiple clinical-stage programs using its GeneTAC gene-targeted chimera platform, with trials ongoing for corneal dystrophy and myotonic dystrophy treatments, and dosing expected to begin for its Huntington's disease program in the first half of 2026.

GlobeNewswire Inc.

Design Therapeutics to Participate in Upcoming Investor Conferences

Design Therapeutics plans to initiate patient dosing for DT-818, a potential treatment for Myotonic Dystrophy Type-1, in the first half of 2026. The company has obtained ex-US regulatory clearance and is developing gene-targeted therapies for various genetic diseases.

GlobeNewswire Inc.

Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 RBC Capital Markets Healthcare Conference on Wednesday, May 15, 2024, at 11:30 a.m. ET in New York.

Benzinga

Design Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying

The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. FTC Solar The Trade: FTC Solar, Inc. (NASDAQ: FTCI) Director Ahmad R Chatila acquired a total of 92,600 shares an average price of $0.55. To acquire these shares, it cost around $50,930. What’s Happening: On March 13, FTC ...

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.